Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
出版年份 2019 全文链接
标题
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-05-31
DOI
10.3389/fimmu.2019.01205
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced Fc effector functions
- (2018) Young Min Kim et al. BIOMATERIALS
- Can IL-15 superagonist ALTer GVL?
- (2018) Robert J. Soiffer BLOOD
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
- (2018) May Daher et al. CURRENT OPINION IN IMMUNOLOGY
- Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
- (2018) Shivani Srivastava et al. JOURNAL OF IMMUNOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells
- (2018) Jens H.W. Pahl et al. Cancer Immunology Research
- A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
- (2018) Wing Keung Chan et al. Cancer Immunology Research
- Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells
- (2018) Liya Zhu et al. Frontiers in Immunology
- Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
- (2018) Muhammad Umair Mushtaq et al. Journal for ImmunoTherapy of Cancer
- Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
- (2018) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural Killer Cells: Development, Maturation, and Clinical Utilization
- (2018) Alex M. Abel et al. Frontiers in Immunology
- Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
- (2018) Nayoung Kim et al. Frontiers in Immunology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells
- (2017) Tina Nham et al. JOURNAL OF IMMUNOTHERAPY
- MP15-12 PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAÏVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC).
- (2017) Charles J. Rosser et al. JOURNAL OF UROLOGY
- Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
- (2017) Laura Chiossone et al. SEMINARS IN IMMUNOLOGY
- Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
- (2017) Zachary B. Davis et al. SEMINARS IN IMMUNOLOGY
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
- (2017) Loredana Cifaldi et al. TRENDS IN MOLECULAR MEDICINE
- The Common Cytokine Receptor γ Chain Family of Cytokines
- (2017) Jian-Xin Lin et al. Cold Spring Harbor Perspectives in Biology
- Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma
- (2017) Liya Zhu et al. Theranostics
- Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
- (2017) Olaf Oberschmidt et al. Frontiers in Immunology
- Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
- (2017) Congcong Zhang et al. Frontiers in Immunology
- Genetically Engineered Multivalent Proteins for Targeted Immunotherapy
- (2016) J. E. Talmadge CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
- (2016) M. Carlsten et al. CLINICAL CANCER RESEARCH
- “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
- (2016) Archana Thakur et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
- (2016) S P Koerner et al. LEUKEMIA
- Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
- (2016) Joerg U Schmohl et al. MOLECULAR THERAPY
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
- (2016) Reza Ghasemi et al. Nature Communications
- An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
- (2016) Caroline Jochems et al. Oncotarget
- TriKEs and BiKEs join CARs on the cancer immunotherapy highway
- (2016) Szun Szun Tay et al. Human Vaccines & Immunotherapeutics
- IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
- (2016) G. C. Sim et al. Cancer Immunology Research
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
- (2016) Sebastian Carotta Frontiers in Immunology
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- Natural killer cell immunotherapy to target stem-like tumor cells
- (2016) Steven K. Grossenbacher et al. Journal for ImmunoTherapy of Cancer
- Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions
- (2015) Bence György et al. Annual Review of Pharmacology and Toxicology
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
- (2015) Garnet Suck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural Killer Cell Adoptive Transfer Therapy
- (2015) Zachary B. Davis et al. CANCER JOURNAL
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Natural Killer Cell Memory
- (2015) Timothy E. O’Sullivan et al. IMMUNITY
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio
- (2015) Tianzhi Yang et al. PHARMACEUTICAL RESEARCH
- Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
- (2015) Alice Tzeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12
- (2015) Theofanis Floros et al. SEMINARS IN ONCOLOGY
- Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
- (2015) David L. Hermanson et al. STEM CELLS
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
- (2015) David L. Hermanson et al. Frontiers in Immunology
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
- (2015) Sabrina Genßler et al. OncoImmunology
- Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
- (2014) N. N. Shah et al. BLOOD
- Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
- (2014) W. Leung CLINICAL CANCER RESEARCH
- Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
- (2014) Y. Mao et al. CLINICAL CANCER RESEARCH
- Effect of tumor cells and tumor microenvironment on NK-cell function
- (2014) Massimo Vitale et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
- (2014) Sawa Ito et al. MOLECULAR THERAPY
- Human natural killer cell development in secondary lymphoid tissues
- (2014) Aharon G. Freud et al. SEMINARS IN IMMUNOLOGY
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
- (2014) I. Melero et al. Cancer Discovery
- Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective
- (2014) Cristina Eguizabal et al. Frontiers in Immunology
- Are natural killer cells superior CAR drivers?
- (2014) Hans Klingemann OncoImmunology
- Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1
- (2013) Yibing Xu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin
- (2013) Shivani Srivastava et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- NK cell-based immunotherapy for malignant diseases
- (2013) Min Cheng et al. Cellular & Molecular Immunology
- Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
- (2013) A. Wiernik et al. CLINICAL CANCER RESEARCH
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Natural killer cell biology: An update and future directions
- (2013) Kerry S. Campbell et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
- (2013) Marco L. Davila et al. PLoS One
- IGF-1 promotes the development and cytotoxic activity of human NK cells
- (2013) Fang Ni et al. Nature Communications
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- The Ly49 Gene Family. A Brief Guide to the Nomenclature, Genetics, and Role in Intracellular Infection
- (2013) Alan Rowe Schenkel et al. Frontiers in Immunology
- The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+T cells into innate-like effector cells with antitumor activity
- (2013) Hing C Wong et al. OncoImmunology
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Immune Surveillance Properties of Human NK Cell-Derived Exosomes
- (2012) L. Lugini et al. JOURNAL OF IMMUNOLOGY
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- NK cell-released exosomes
- (2012) Stefano Fais OncoImmunology
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
- (2011) Christian Kellner et al. CANCER LETTERS
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations
- (2011) Kerry S. Campbell et al. IMMUNOLOGY
- Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
- (2011) Lydia Alvarez-Erviti et al. NATURE BIOTECHNOLOGY
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery
- (2010) Francesca Raimondo et al. PROTEOMICS
- Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
- (2009) P. S. Woll et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Regulation of human NK-cell cytokine and chemokine production by target cell recognition
- (2009) C. Fauriat et al. BLOOD
- Platelet-Derived Transforming Growth Factor- Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
- (2009) H.-G. Kopp et al. CANCER RESEARCH
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
- (2009) R. W. McGilvray et al. CLINICAL CANCER RESEARCH
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
- (2009) B. Altvater et al. CLINICAL CANCER RESEARCH
- Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells
- (2009) Isabella Parolini et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exosome Function: From Tumor Immunology to Pathogen Biology
- (2008) Jeffrey S. Schorey et al. TRAFFIC
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now